세계 임상시험수탁기관(CRO) 서비스 시장 규모는 2023년 700억 7,000만 달러에서 2031년 1,359억 1,000만 달러에 이르고, 2024-2031년의 예측 기간 동안 연평균 8.63% 성장할 전망입니다. 기술 강화에 대한 관심 증가, 확장을 위한 자금 확보, 임상 연구 서비스에 대한 수요 증가, 암에 대한 사용 증가, 유럽 시장 성장, M&A 증가 등 다양한 요인이 시장을 형성하고 있습니다.
기술 채택이 증가함에 따라 시장이 성장하고 있으며, CRO는 임상시험을 변화시키는 혁신적인 기술을 도입하여 업계를 선도하고 있으며, CRO는 AI, 머신러닝, 클라우드 컴퓨팅의 융합을 통해 절차를 최적화하고 데이터 분석을 개선하며 더 나은 의사결정을 내릴 수 있게 되었습니다. 더 나은 의사결정을 내릴 수 있게 되었습니다. 이러한 기술 혁명으로 CRO는 고객에게 보다 효과적이고 진보된 데이터 기반 서비스를 제공할 수 있게 되었으며, CRO는 생명공학 및 제약 부문의 변화하는 수요에 대응하기 위해 서비스를 다양화하고, 희귀질환, 세포 및 유전자 치료, 실제 임상 증거 생성 등 새로운 분야에 특화된 CRO를 설립하고 있습니다. 실제 임상 근거 창출과 같은 새로운 분야에 특화된 서비스를 제공합니다. 이러한 다각화를 통해 CRO는 경쟁사들과 차별화할 수 있으며, 확대되는 세계 CRO 서비스 시장에서 더 큰 점유율을 확보할 수 있습니다.
CRO는 다양한 환자 집단과 규제 당국의 상황에 접근하기 위해 세계 실적를 구축하고 있습니다. 동시에 현지 시장 수요에 맞는 서비스를 제공하고 현지 법률과 관습을 준수할 수 있도록 하고 있습니다. 이러한 세계 전략은 CRO가 어디서나 일관된 품질 기준을 유지하면서 고객에게 맞춤형 솔루션을 제공할 수 있게 함으로써 세계 CRO 서비스 시장의 성장에 기여하고 있습니다. 연구 참여자의 안전과 임상시험 데이터의 정확성을 보장하기 위해 규제 준수와 품질 관리 시스템을 우선시하고 있습니다. 강력한 데이터 관리 절차를 도입하고, 엄격한 품질 관리 절차를 채택하고, 규제 기관과 긴밀하게 협력하고 있습니다. 세계 임상시험수탁기관(CRO) 서비스 시장에서 명성을 유지하고 스폰서의 반복적인 거래를 확보하기 위해 CRO는 품질과 컴플라이언스에 대한 헌신을 견지해야 합니다.
예를 들어, 생체인식 CRO인 Quantitativeate International Ltd.는 2024년 4월 임상시험용 소프트웨어를 개발하는 머신러닝 기업 PhaseV Trials Ltd. Trials Ltd.와 파트너십을 체결했다고 발표했습니다. 양사는 PhaseV의 머신러닝 플랫폼과 소프트웨어를 Quanticate의 통계 프로그래밍, 생물통계학, 임상 데이터 관리 솔루션과 결합하여 Quanticate의 통계 컨설턴트가 의뢰자의 임상시험이 적응형 설계에 적합한지 여부를 판단할 수 있는 새로운 시스템을 구축할 예정입니다. 판단할 수 있는 새로운 시스템을 구축하는 것을 목표로 하고 있습니다. 중간 데이터에 따라 설계를 조정하는 임상시험을 적응형 임상시험이라고 합니다.
시장에서의 기술 강화에 대한 관심 증대
세계 임상시험수탁기관(CRO) 서비스 시장은 업계 성장을 가속화할 수 있는 큰 기술적 전환을 맞이하고 있습니다. CRO는 임상시험의 여러 분야를 개선하기 위해 AI와 ML을 워크플로우에 활용하고 있으며, AI 기반 플랫폼은 환자 모집을 개선하고, 안전성 경고를 보다 신속하게 식별하며, 실제 임상 증거를 보다 효율적으로 제공할 수 있는 잠재력을 가지고 있습니다. 이를 통해 CRO는 고객에게 고급 데이터 기반 서비스를 제공할 수 있습니다. CRO는 데이터 저장, 분석 및 관리를 개선하기 위해 클라우드 기반 솔루션으로 전환하고 있습니다. 이를 통해 임상시험에서 보다 효율적인 데이터 처리, 팀워크 강화, 정보에 입각한 의사결정을 할 수 있게 됩니다.
이 보고서는 세계 CRO(Contract Research Organization) 서비스 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황과 전망 등을 전해드립니다.
Global contract research organization (CRO) services market is projected to witness a CAGR of 8.63% during the forecast period 2024-2031F, growing from USD 70.07 billion in 2023 to USD 135.91 billion in 2031F. Various factors shape the global CRO services market, including an increased focus on technological enhancements, companies securing funding for expansion, increased demand for clinical research services, a rise in applications in oncology, a growing European market, and increasing mergers and acquisitions.
The global CRO services market is growing because of the increasing adoption of technology. CROs are leading the way in implementing innovative technologies to transform clinical trials. CROs are better positioned to optimize procedures, improve data analysis, and make better decisions thanks to the convergence of artificial intelligence, machine learning, and cloud computing. Due to this technological revolution, CROs can now offer their clients more advanced, effective, and data-driven services. CROs are diversifying their offerings to meet the changing demands of the biotech and pharmaceutical sectors. They provide specialized services in new fields such as rare diseases, cell and gene therapies, and the creation of real-world evidence. By diversifying, CROs can set themselves apart from rivals and take a bigger chunk of the expanding global CRO services market.
To access a variety of patient populations and regulatory contexts, CROs are creating a global footprint. Simultaneously, they are tailoring their offerings to suit the local market's demands and ensuring that local laws and customs are followed. With the help of this global strategy, CROs can provide their clients with customized solutions while upholding uniform quality standards everywhere, leading to growth in the global CRO services market. CROs are prioritizing regulatory compliance and quality management systems to guarantee research participant safety and the accuracy of clinical trial data. They are putting strong data management procedures into place, employing strict quality control procedures, and working closely with regulatory bodies. To keep their good name and win sponsors' recurring business in the global CRO services market, CROs must remain steadfast in their dedication to quality and compliance.
For example, to introduce a new service that intends to assist sponsors in designing and optimizing adaptive trials, biometric CRO Quanticate International Ltd. announced in April 2024 that it has partnered with PhaseV Trials Ltd., a machine learning firm that develops software for clinical trials. The companies aim to combine PhaseV's machine learning platform and software with Quanticate's statistical programming, biostatistics, and clinical data management solutions to create a new system that will enable Quanticate's statistical consultants to determine whether a sponsor's trial is appropriate for an adaptive design. Clinical trials that adapt their designs in response to interim data are known as adaptive trials.
Increased Focus on Technological Enhancements in the Market
The global CRO services market is undergoing a major technological transition that is accelerating the growth in the industry. To improve several areas of clinical trials, CROs are increasingly using AI and ML in their workflows. AI-driven platforms have the potential to improve patient recruitment, identify safety warnings more quickly, and provide real-world evidence more efficiently. This makes it possible for CROs to offer their clients more advanced, data-driven services. To improve data storage, analytics, and management, CROs are moving to cloud-based solutions. During clinical trials, this enables more effective data processing, enhanced teamwork, and more informed decision-making.
For example, the global oncology research leader, Sarah Cannon Research Institute (SCRI), which conducts community-based clinical trials, announced in February 2024 that it is partnering with AstraZeneca Plc, a science-led biopharmaceutical company, to advance innovative technology and operational synergies to improve oncology clinical trial delivery. Together, AstraZeneca and SCRI will put cutting-edge strategies into practice to improve U.S. recruitment, lessen site burden, and expedite clinical trial delivery schedules.
Companies are Securing Funding for Expansion in the Market
Various companies in the industry are securing funds to grow in the global CRO services market. CROs are using funding to diversify the services and skills they offer. This enables them to address a greater variety of client needs in various therapeutic domains and phases of the medication development process. CROs are making investments in the integration of cutting-edge technology, such as cloud computing, machine learning, and artificial intelligence. As a result, their clinical trial services are more accurate, efficient, and data driven. Funding is being used by CROs to establish specialized teams and infrastructure aimed at therapeutic domains, like oncology, illnesses of the central nervous system, and uncommon diseases. Their subject experience makes them more appealing as partners to clients in the biotech and pharmaceutical industries.
For example, Manifold Inc., a clinical research platform driven by artificial intelligence, obtained USD 15 million in series A funding in April 2024 to form alliances with healthcare institutions. TQ Ventures led the investment round. With the Series A funding, Manifold intends to expand its collaborations with cancer centers and other healthcare institutions and make investments in research and development to add new features and capabilities.
Increased Demand for Clinical Research Services in the Market
There are several factors responsible for the high demand for clinical research services in the global CRO services market. The increased prevalence of chronic diseases like cardiovascular diseases, cancer, etc., has increased the importance of clinical research studies. Clinical research studies aid in the growth of evidence-based medicine, which helps medical professionals make more educated treatment decisions. The development of precision or personalized medicine, in which patient traits are considered while designing therapies, is aided by clinical research. Due to the treatments' improved fit for the patient's genetic profile, lifestyle, and other pertinent variables, this strategy may result in more potent therapies with fewer adverse effects.
For instance, Medidata Solutions Inc., a provider of clinical trial data solutions, extended its long-term agreement with Pharmaceutical Product Development (PPD), Thermo Fisher Scientific Inc.'s clinical research organization, in February 2024. The agreement reaffirms their continuous co-development of PPD TrueCast, an artificial intelligence solution for clinical trials, and permits the CRO to continue using Medidata's core platform. Medidata has established a valuable relationship with the PPD clinical research industry to improve visibility and decision-making during clinical trials.
Rising Application in Oncology is Driving Market Growth
Many CROs have acquired specific knowledge and experience in managing clinical trials related to cancer. They have assembled specialized groups of clinicians, scientists, and support personnel who are committed to addressing the difficulties associated with cancer research. CROs frequently have a deep network of established connections with community-based and academic clinical trial sites spread throughout numerous areas. This enables them to conduct cancer research on a variety of patient populations. To increase the effectiveness and caliber of oncology clinical trials, CROs are making investments in cutting-edge technology, including artificial intelligence, digital data management platforms, and remote monitoring tools. All these factors make oncology an important subject of the industry, driving the growth of the global CRO services market.
For instance, Harvest Integrated Research Organization (HiRO), a cutting-edge international contract research organization (CRO) with headquarters in China, announced in September 2023 that it has successfully acquired Courante Oncology, a full-service clinical research provider with headquarters in the US that specializes in oncology product development. HiRO's acquisition of Courante Oncology is a big step in the right direction as it works to establish itself as a major worldwide CRO. With increased capabilities and a stronger presence in the US, HiRO is well positioned to provide its clients with cutting-edge, quick clinical trial solutions anywhere in the world.
European Region to Grow Exponentially in the Forecast Period
It is anticipated that the CRO services market will grow exponentially in the European region in the future, driving the overall growth of the global CRO services market. The growing incidence of chronic diseases, rising healthcare costs, and the trend towards outsourcing clinical research operations are all contributing to the growth of the European clinical trials market. To take advantage of the growing demand for their services, CROs are being drawn to strengthen their presence in Europe as a result of this growing market opportunity. It is becoming simpler for CROs to conduct business in several European nations due to the harmonization of clinical trial laws throughout the continent, which is made possible by programs like the Clinical Trials Regulation (CTR) in the European Union.
For example, the acquisition of Heads Research, a privately held European contract research organization (CRO) that specializes in cancer clinical trials, was announced in March 2024 by Veeda Clinical Research Limited, a full-service CRO with a track record of success in drug development. With this acquisition, Veeda joins the elite group of international contract research organizations (CROs) that offer comprehensive capabilities to provide contract research services ranging from post-commercial launch to clinical development and discovery.
Future Market Scenario (2024-2031F)
The global CRO services market is growing because CROs are expanding their specialized knowledge and skills into therapeutic domains other than cancer, such as cell and gene therapies, uncommon illnesses, and central nervous system disorders.
It is anticipated that the global CRO services market will continue to grow because many CROs plan to implement decentralized and hybrid clinical trial models.
It is expected that the global CRO services market will grow because Environmental, social, and governance (ESG) concepts and sustainability are being integrated by CROs more and more into their commercial operations.
CROs are fortifying their position in these areas like Asia, Latin America and Africa to grow in the global CRO services market and take advantage of the rising demand for clinical research services in the emerging markets.
Key Players Landscape and Outlook
The global CRO services market has observed many mergers and acquisitions in recent times. Smaller, more niche CROs are being bought out by larger CROs to diversify their offerings. This enables them to provide their clientele with a more complete range of solutions. The larger CROs can obtain new technology and methods or acquire experience in particular therapeutic areas, like cancer, by acquiring niche players. Through acquisitions, larger CROs can enter new markets and extend their geographic reach. This is especially crucial as the global market for clinical trials expands. In addition to giving larger CROs a footing in new markets, smaller CROs with a strong local or regional presence can help them service customers more efficiently across many locations.
For example, American Clinical Research Services (ACRS), a renowned multi-specialty clinical research network with operations spanning Florida, Massachusetts, Michigan, and Missouri, successfully acquired Elixia Tech Solutions Ltd. in May 2024. ACRS is a leader in complex clinical research and was founded by Latticework Capital Management (LCM). Elixia's collaboration with ACRS strengthens their shared dedication to furthering research in difficult therapeutic areas. Through this combination, it will be able to launch and maintain studies that have the potential to significantly improve patient outcomes, as well as increase site capabilities and resources.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.